Gestational angiogenic biomarker patterns in high risk preeclampsia groups

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Reproductive Biology

Background:

• Preeclampsia (PE) is a serious pregnancy complication with various associated risk factors.
• The role of maternal angiogenic factor levels in these high-risk conditions remains unclear.
• Understanding these factors may offer insights into PE pathogenesis.

Purpose of the Study:

• To compare angiogenic biomarker patterns in pregnancies with preeclampsia risk factors versus low-risk controls.
• To investigate specific biomarkers: soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin (sEng), and placental growth factor (PlGF).
• To analyze biomarker profiles across different gestational windows.

Main Methods:

• Secondary analysis of a 2-center observational study involving 156 high-risk and 59 low-risk pregnant women.
• Serial maternal serum samples collected at 23-27, 28-31, and 32-35 weeks of gestation.
• Quantification of sFlt1, sEng, and PlGF using enzyme-linked immunosorbent assay; calculation of the angiogenic ratio (sFlt1 + sEng):PlGF.

Main Results:

• Distinct gestational biomarker patterns were identified in PE risk groups compared to controls.
• Multiple gestations were associated with higher sFlt1 and sEng levels throughout gestation.
• Prior PE correlated with elevated sFlt1 and angiogenic ratio, and reduced PlGF from 28 weeks onward.
• Chronic hypertension showed a higher angiogenic ratio, but this normalized when PE cases were excluded.
• Obesity and nulliparity were linked to lower PlGF but not altered angiogenic ratio.

Conclusions:

• Altered angiogenic biomarker profiles are present in various high-risk pregnancy groups.
• These changes suggest that dysregulated production or metabolism of angiogenic factors may contribute to preeclampsia risk.
• The findings are particularly relevant for women with multiple gestations and a history of preeclampsia.